Bone metastases in endometrial cancer

Report on 19 patients and review of the medical literature

Stefano Uccella, Jonathan M. Morris, Jamie N Bakkum-Gamez, Gary Keeney, Karl C. Podratz, Andrea Mariani

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Objective Because few cases of bone metastases of endometrial cancer have been reported, and information is scarce on their incidence, treatment, prognosis, and outcomes, we sought to compile a series of bone metastases of endometrial cancer and to systematically review the medical literature. Methods We retrospectively reviewed medical records of patients who had osseous metastases of endometrial cancer treated initially at Mayo Clinic (1984-2001), and of all patients who were referred for treatment of primary bone metastases after primary treatment for endometrial cancer elsewhere. Results Of 1632 patients with endometrial cancer, 13 (0.8%) had primary bone dissemination and 6 (0.4%) were referred after initial treatment. Three (15.8%) of these 19 had bone metastases at presentation; in the rest, median time to recurrence was 19.5 months (range, 3-114). The most common sites were the spine and hip. Median survival after metastasis was 12 months (range, 2-267). Median survival after radiotherapy alone vs. multimodal treatment was 20 months (range, 12-119) vs. 33 months (range, 9-267), respectively (P >.99). Of the 87 cases we reviewed from the literature, all but 1 (98.9%) had diagnoses based on symptoms. Multiple bone involvement and extraosseous dissemination were associated with poor prognosis. Type II endometrial cancer (i.e., serous or clear-cell histology) was associated with shorter life expectancy after diagnosis of bone metastasis compared to Type I tumors. Conclusions The incidence of primary bone metastases of endometrial cancer is < 1%. Single bone metastases without extraosseous spread indicate less aggressive disease. Optimal treatment is unclear.

Original languageEnglish (US)
Pages (from-to)474-482
Number of pages9
JournalGynecologic Oncology
Volume130
Issue number3
DOIs
StatePublished - Sep 2013

Fingerprint

Endometrial Neoplasms
Neoplasm Metastasis
Bone and Bones
Combined Modality Therapy
Survival
Incidence
Therapeutics
Life Expectancy
Medical Records
Hip
Histology
Spine
Radiotherapy
Recurrence

Keywords

  • Bone
  • Endometrial neoplasms
  • Neoplasm metastases
  • Osseous
  • Prognosis

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Bone metastases in endometrial cancer : Report on 19 patients and review of the medical literature. / Uccella, Stefano; Morris, Jonathan M.; Bakkum-Gamez, Jamie N; Keeney, Gary; Podratz, Karl C.; Mariani, Andrea.

In: Gynecologic Oncology, Vol. 130, No. 3, 09.2013, p. 474-482.

Research output: Contribution to journalArticle

Uccella, Stefano ; Morris, Jonathan M. ; Bakkum-Gamez, Jamie N ; Keeney, Gary ; Podratz, Karl C. ; Mariani, Andrea. / Bone metastases in endometrial cancer : Report on 19 patients and review of the medical literature. In: Gynecologic Oncology. 2013 ; Vol. 130, No. 3. pp. 474-482.
@article{f24047ab85e24cefbb0e447372b62926,
title = "Bone metastases in endometrial cancer: Report on 19 patients and review of the medical literature",
abstract = "Objective Because few cases of bone metastases of endometrial cancer have been reported, and information is scarce on their incidence, treatment, prognosis, and outcomes, we sought to compile a series of bone metastases of endometrial cancer and to systematically review the medical literature. Methods We retrospectively reviewed medical records of patients who had osseous metastases of endometrial cancer treated initially at Mayo Clinic (1984-2001), and of all patients who were referred for treatment of primary bone metastases after primary treatment for endometrial cancer elsewhere. Results Of 1632 patients with endometrial cancer, 13 (0.8{\%}) had primary bone dissemination and 6 (0.4{\%}) were referred after initial treatment. Three (15.8{\%}) of these 19 had bone metastases at presentation; in the rest, median time to recurrence was 19.5 months (range, 3-114). The most common sites were the spine and hip. Median survival after metastasis was 12 months (range, 2-267). Median survival after radiotherapy alone vs. multimodal treatment was 20 months (range, 12-119) vs. 33 months (range, 9-267), respectively (P >.99). Of the 87 cases we reviewed from the literature, all but 1 (98.9{\%}) had diagnoses based on symptoms. Multiple bone involvement and extraosseous dissemination were associated with poor prognosis. Type II endometrial cancer (i.e., serous or clear-cell histology) was associated with shorter life expectancy after diagnosis of bone metastasis compared to Type I tumors. Conclusions The incidence of primary bone metastases of endometrial cancer is < 1{\%}. Single bone metastases without extraosseous spread indicate less aggressive disease. Optimal treatment is unclear.",
keywords = "Bone, Endometrial neoplasms, Neoplasm metastases, Osseous, Prognosis",
author = "Stefano Uccella and Morris, {Jonathan M.} and Bakkum-Gamez, {Jamie N} and Gary Keeney and Podratz, {Karl C.} and Andrea Mariani",
year = "2013",
month = "9",
doi = "10.1016/j.ygyno.2013.05.010",
language = "English (US)",
volume = "130",
pages = "474--482",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Bone metastases in endometrial cancer

T2 - Report on 19 patients and review of the medical literature

AU - Uccella, Stefano

AU - Morris, Jonathan M.

AU - Bakkum-Gamez, Jamie N

AU - Keeney, Gary

AU - Podratz, Karl C.

AU - Mariani, Andrea

PY - 2013/9

Y1 - 2013/9

N2 - Objective Because few cases of bone metastases of endometrial cancer have been reported, and information is scarce on their incidence, treatment, prognosis, and outcomes, we sought to compile a series of bone metastases of endometrial cancer and to systematically review the medical literature. Methods We retrospectively reviewed medical records of patients who had osseous metastases of endometrial cancer treated initially at Mayo Clinic (1984-2001), and of all patients who were referred for treatment of primary bone metastases after primary treatment for endometrial cancer elsewhere. Results Of 1632 patients with endometrial cancer, 13 (0.8%) had primary bone dissemination and 6 (0.4%) were referred after initial treatment. Three (15.8%) of these 19 had bone metastases at presentation; in the rest, median time to recurrence was 19.5 months (range, 3-114). The most common sites were the spine and hip. Median survival after metastasis was 12 months (range, 2-267). Median survival after radiotherapy alone vs. multimodal treatment was 20 months (range, 12-119) vs. 33 months (range, 9-267), respectively (P >.99). Of the 87 cases we reviewed from the literature, all but 1 (98.9%) had diagnoses based on symptoms. Multiple bone involvement and extraosseous dissemination were associated with poor prognosis. Type II endometrial cancer (i.e., serous or clear-cell histology) was associated with shorter life expectancy after diagnosis of bone metastasis compared to Type I tumors. Conclusions The incidence of primary bone metastases of endometrial cancer is < 1%. Single bone metastases without extraosseous spread indicate less aggressive disease. Optimal treatment is unclear.

AB - Objective Because few cases of bone metastases of endometrial cancer have been reported, and information is scarce on their incidence, treatment, prognosis, and outcomes, we sought to compile a series of bone metastases of endometrial cancer and to systematically review the medical literature. Methods We retrospectively reviewed medical records of patients who had osseous metastases of endometrial cancer treated initially at Mayo Clinic (1984-2001), and of all patients who were referred for treatment of primary bone metastases after primary treatment for endometrial cancer elsewhere. Results Of 1632 patients with endometrial cancer, 13 (0.8%) had primary bone dissemination and 6 (0.4%) were referred after initial treatment. Three (15.8%) of these 19 had bone metastases at presentation; in the rest, median time to recurrence was 19.5 months (range, 3-114). The most common sites were the spine and hip. Median survival after metastasis was 12 months (range, 2-267). Median survival after radiotherapy alone vs. multimodal treatment was 20 months (range, 12-119) vs. 33 months (range, 9-267), respectively (P >.99). Of the 87 cases we reviewed from the literature, all but 1 (98.9%) had diagnoses based on symptoms. Multiple bone involvement and extraosseous dissemination were associated with poor prognosis. Type II endometrial cancer (i.e., serous or clear-cell histology) was associated with shorter life expectancy after diagnosis of bone metastasis compared to Type I tumors. Conclusions The incidence of primary bone metastases of endometrial cancer is < 1%. Single bone metastases without extraosseous spread indicate less aggressive disease. Optimal treatment is unclear.

KW - Bone

KW - Endometrial neoplasms

KW - Neoplasm metastases

KW - Osseous

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84882453838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882453838&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2013.05.010

DO - 10.1016/j.ygyno.2013.05.010

M3 - Article

VL - 130

SP - 474

EP - 482

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -